How to Design an ABM-Aligned Ideal Customer Profile (ICP) 

Every December, the business development team at a mid-size contract research organization would gather at a hotel for their annual planning meeting. Over three days, each BD rep would stand up and present their account priorities for the coming year: which companies they were going after, which they were treating as top-tier targets, and why. The problem was that every rep had developed their own criteria. Some prioritized large pharma because of deal size. Others focused on mid-size biotechs because they were easier to get meetings with. Some tiered accounts based on geography. Others based it on relationships. The result was a fragmented, inconsistent commercial strategy that made it nearly impossible for marketing to support in any coordinated way.

When a structured ABM program was proposed to support the sales team, the first task wasn't setting up a platform or designing ads. It was building a shared, data-backed targeting framework — a real ICP — derived from analysis of which accounts had historically generated the most revenue, what their shared characteristics were, and how to translate those characteristics into consistent, actionable targeting criteria for the whole team.

That work transformed the annual planning process. It also provided the foundation that made everything else in the ABM program possible.

Why the ICP Is the Foundation of Everything in ABM

Account-based marketing lives or dies on targeting precision. Every subsequent decision in an ABM program including which accounts to include, what messaging to develop, which personas to reach, and how to structure campaigns flows from a clear, specific, commercially-grounded ICP.

Most B2B organizations have something they call an ICP. The problem is that those ICPs are often undocumented, outdated, or built more on assumptions and intuition than on actual business data. In life sciences especially, where market conditions shift with funding cycles, therapeutic pipeline evolution, and regulatory changes, an ICP that was accurate two years ago may no longer reflect the real profile of your best customers today.

The most important step in building a strong ICP is the one most often skipped: go back to your own revenue data and let it tell you who your best customers actually are.

Start With the 80/20 Analysis

In most B2B organizations, revenue distribution follows a pattern: roughly 80% of revenue comes from approximately 20% of accounts. That top 20% of accounts with the largest contracts, the best retention, and the strongest expansion history is an ideal starting point for your ICP.

Pull the data. Look at your highest-revenue accounts over the past two to three years. Look at average deal value by account, time to close, repeat business, and account expansion. Identify the top accounts and then look carefully at what they have in common. The commonalities and features of these accounts are what forms the core of your ICP, and accounts that look like these should be your priority target accounts.

From there, broaden the ICP. Define the strong-fit companies that represent meaningful revenue potential but don't quite match the profile of your very best customers. And also include definitions for the broad universe of accounts that you have and can sell to. Accounts fitting these criteria will end up being accounts worth reaching with broad, scalable marketing but don't warrant the level of marketing investment that the best fit accounts will.

What an ABM-Aligned ICP Looks Like for Pharma and Biotech Companies

Generic B2B ICP frameworks typically focus on firmographic criteria like company size, industry vertical, revenue range, and geography. In life sciences, these firmographics are a starting point, but the most meaningful targeting criteria are considerably more specific. 

The following factors are commonly relevant when building ICP criteria for pharma and biotech targets:

Pipeline stage and asset maturity. For many life science service and technology providers, the most relevant signal is where a target company's assets sit in development. A company with three programs in early discovery is a very different prospect than one with a Phase 2 asset that just received FDA Fast Track designation. Depending on your offering, you may find that accounts with assets at a specific stage (late preclinical, Phase 1/2, or pre-NDA, for example) are consistently your best customers. Documenting that stage specificity in your ICP sharpens targeting significantly.

Therapeutic area and modality. Not all pipelines are created equal from a targeting perspective. If your solution has particular depth in oncology biomarker work, a company developing cardiovascular small molecules may be a technically eligible but strategically poor fit. ICP segments based on therapeutic area (oncology, rare disease, neurology, immunology, etc.) and modality (small molecule, biologics, cell therapy, gene therapy, antibody-drug conjugates) allow you to match your specific expertise and capability to the accounts most likely to value it.

Company size and organizational maturity. Headcount and revenue are useful proxies, but for biotech specifically, pipeline size and funding stage are often more meaningful. A 200-person biotech with a single Phase 3 asset and a recent Series D is a different proposition than a 200-person biotech running four early-phase programs on a Series B runway. Commercial maturity matters too: a company with a dedicated clinical operations team and an established outsourcing function will have a faster path to vendor selection than one building those capabilities for the first time.

Funding status and financial signals. Recent funding events are often strong signals of an upcoming purchasing need in life science ABM. A Series C or D round, a successful IPO, or a significant partnership or licensing deal typically signals that capital has been allocated to advance programs. Investment in supporting services and technologies is likely to follow. Companies without recent funding events, or with visible financial stress (layoffs, program cancellations, strategic reviews), are lower-priority targets regardless of how well they fit other ICP criteria.

Outsourcing orientation. Some companies build in-house capability wherever possible; others run lean and outsource heavily. If you are a CRO, a central lab, or a technology vendor, knowing whether a target company has a history of outsourcing work similar to yours is an important qualifying criterion. This can often be inferred from job postings, LinkedIn profiles of the commercial team, or known relationships with peer organizations.

Geography and regulatory context. Clinical trial activity, site networks, and regulatory strategy can all vary significantly by geography. If your solution has particular depth in EU regulatory pathways, or your service infrastructure is concentrated in North America, this should be reflected in your ICP rather than targeting globally and filtering retroactively.

Segmenting When Your Value Proposition Varies

An important distinction that is frequently overlooked in ICP construction: if your organization offers multiple products or services with meaningfully different value propositions, a single monolithic ICP won't serve you well. You need segmented ICPs with one for each major audience group, and distinct messaging frameworks for each.

A contract service organization offering both early-phase bioanalytical services and late-phase central lab services, for example, is effectively selling to two different audiences with different stages of need, different buying committee compositions, and different primary concerns. Treating those as one audience produces messaging that is generic to both and compelling to neither.

Each segmented ICP should document: the firmographic and life sciences-specific profile of the segment, the typical buying committee composition, the primary business challenges driving a need for your solution, and the core value propositions most relevant to that audience. This segmentation becomes the blueprint for everything downstream: persona targeting, content development, ad messaging, and landing page design.

Account Tiering: Not All ICP Accounts Are Equal

Once you have a working ICP with any relevant segments, the next step is to recognize that even among accounts that all meet your criteria, there is a wide range in terms of potential deal value, strategic importance, and sales readiness. Treating every qualifying account with the same level of marketing investment is a recipe for poor ROI. This is where account tiering comes in - and it can flow from the 80/20 analysis and best-fit ICP definitions created earlier.

In ABM, tiering divides your ICP account list into groups that warrant different levels of commercial resource, and directly determines which ABM approach (One-to-One, One-to-Few, or One-to-Many) is applied to each group.

A common and effective framework uses three tiers:

Tier 1 — Strategic. These are your highest-value targets: accounts with the potential for exceptionally large, multi-year engagements that would represent a material impact on annual revenue. They represent a perfect match with your strongest service or product capabilities, at exactly the right stage of development. Accounts worthy of an ABM 1:1 investment are typically few and often no more than 5 to 10 accounts, and rarely more than 5% of your total ICP list. Because the revenue potential justifies it, these accounts receive a fully bespoke One-to-One ABM treatment: customized landing pages, account-specific content, and executive-level BD engagement.

Tier 2 — Scale. The next 20 to 30% of your ICP list falls here. These accounts have strong clinical and scientific fit, a high likelihood of closing, and represent healthy deal values with good operational alignment. They may not individually justify the resource intensity of Tier 1, but they are by no means generic targets. The appropriate approach is One-to-Few ABM: grouping accounts by a shared characteristic  (the same therapeutic area, the same development phase, the same diagnostic focus) and deploying messaging and content tailored to the needs of that segment.

Tier 3 — Programmatic. The remaining accounts that meet your broad ICP criteria sit in Tier 3. They may not yet demonstrate the revenue potential or buying signals to warrant deeper investment, but they are worth keeping in view. One-to-Many ABM, which uses approaches like broad programmatic advertising, content syndication, and educational webinars, is the right approach here. The goal is dual: build brand awareness within this pool, and monitor for signals (a new funding round, a regulatory filing, a pipeline advancement) that suggest an account is ready to be elevated to Tier 2.

It is worth noting that tiering is not a static assignment. Accounts should move between tiers as market conditions change and new information becomes available. A Tier 3 biotech that closes a Series C and announces a new Phase 2 program is no longer a Tier 3 account. Your commercial team needs a defined process, typically tied to the life-science-specific intent signals discussed in later posts in this series, for identifying when an account should be elevated and what happens next when it is.

The practical value of tiering extends beyond resource allocation. It also creates internal clarity and accountability. Marketing knows which accounts to invest in most deeply. The SDR team knows which qualified accounts are highest priority for outreach. BD knows which opportunities to prioritize for executive engagement. When tiers are agreed upon and documented, the commercial team stops debating priorities and starts executing against them.

Add Persona Targeting to Complete the Picture

An ICP defines which companies to target. Persona targeting defines which people within those companies to reach. Both are required for ABM.

With your ICP segments in place, the next step is to document the buying committee for each segment. These are the typical roles involved in a purchase decision, and the titles that align to each role. Sales and BD input is essential here: they know who is actually in the room when a deal is being decided, whose concerns can stall a deal, and who tends to be the internal champion.

The output is a matrix of ICP segments and persona types, each with associated title keywords for targeting. This becomes the foundation for all persona-level ad targeting, content development, and outreach sequencing in your ABM campaigns.

Treat the ICP as a Living Document

A well-designed ICP is not a one-time exercise. Markets shift, pipelines move, your own offerings evolve, and the profile of your best-fit customer changes accordingly. Building in an annual ICP review with input from marketing, sales, BD, and ideally a commercial leadership sponsor ensures that your ABM program continues to target the right accounts as your business grows.

The companies that get the most from ABM are not always those with the most sophisticated technology or the largest campaign budgets. They are the ones with the clearest, most commercially aligned picture of who they are trying to win, and a process to ensure that picture is kept current.